
Pre-made Burosumab benchmark antibody ( Whole mAb, anti-FGF23 therapeutic antibody, Anti-ADHR/FGFN/HFTC2/HPDR2/HYPF/PHPTC Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-086
Pre-Made Burosumab biosimilar, Whole mAb, Anti-FGF23 Antibody: Anti-ADHR/FGFN/HFTC2/HPDR2/HYPF/PHPTC therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Burosumab (INN, sold under the brand name Crysvita) is a human monoclonal antibody medication for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia.[ Burosumab was approved by the FDA for its intended purpose, in patients aged one year and older, in April 2018.[8] The FDA approval fell under both the breakthrough therapy and orphan drug designations. It was approved for use in the European Union in February 2018.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
GMP-Bios-ab-086-1mg | 1mg | 3090 | ||
GMP-Bios-ab-086-10mg | 10mg | Inquiry | ||
GMP-Bios-ab-086-100mg | 100mg | Inquiry | ||
GMP-Bios-ab-086-xmg | ≥100mg | Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Products Name (INN Index) | Pre-Made Burosumab biosimilar, Whole mAb, Anti-FGF23 Antibody: Anti-ADHR/FGFN/HFTC2/HPDR2/HYPF/PHPTC therapeutic antibody |
INN Name | Burosumab |
Target | FGF23 |
Format | Whole mAb |
Derivation | Human |
Species Reactivity | Human |
CH1 Isotype | IgG1 |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Approved |
Est. Status | Active |
100% SI Structure | None |
99% SI Structure | None |
95-98% SI Structure | None |
Year Proposed | 2016 |
Year Recommended | 2017 |
Companies | Kyowa Hakko Kirin;Ultragenyx Pharmaceutical |
Conditions Approved | X-linked dominant hypophosphataemic rickets;Osteomalacia |
Conditions Active | Nevus |
Conditions Discontinued | na |
Development Tech | na |
- GENEMEDI
- 6th Floor, Building No.2, Kangxin Road 3377, Shanghai, China
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
